AURA · Aura Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $27.96M | - | $22.18M | $22.88M | $23.34M | - | $17.04M | $16.88M | $17.05M | - |
| SG&A | $6.91M | - | $5.73M | $5.73M | $5.69M | - | $6.20M | $5.88M | $5.26M | - |
| Total Operating Expenses | $34.87M | - | $27.91M | $28.61M | $29.04M | - | $23.23M | $22.76M | $22.31M | - |
| D&A | $274.0K | - | $300.0K | $300.0K | $291.0K | - | $300.0K | $300.0K | $306.0K | - |
| Operating Income | ($34.87M) | - | ($27.91M) | ($28.61M) | ($29.04M) | - | ($23.23M) | ($22.76M) | ($22.31M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $11.0K | - | $26.0K | $48.0K | $18.0K | - | $43.0K | - | $46.0K | - |
| Net Income | ($33.69M) | - | ($26.13M) | ($27.02M) | ($27.48M) | - | ($21.04M) | ($20.34M) | ($19.71M) | - |
| EPS - Basic | ($0.50) | - | ($0.40) | ($0.47) | ($0.55) | - | ($0.42) | ($0.41) | ($0.40) | - |
| EPS - Diluted | ($0.50) | - | ($0.40) | ($0.47) | ($0.55) | - | ($0.42) | ($0.41) | ($0.40) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $84.79M | $59.52M | $47.55M | $107.37M | $38.23M | $31.69M | $25.41M | $30.07M | $26.28M | $41.06M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.57M | $1.55M | $1.89M | $1.29M | $2.01M | $2.30M | $1.99M | $1.46M | $1.93M | $1.79M |
| Current Assets | $118.50M | $149.74M | $170.12M | $183.96M | $134.52M | $160.62M | $183.48M | $195.60M | $212.25M | $231.79M |
| Total Assets | $137.68M | $169.43M | $190.02M | $204.40M | $155.40M | $182.50M | $205.34M | $218.28M | $235.03M | $255.07M |
| Current Liabilities | $16.71M | $18.38M | $18.82M | $14.85M | $12.16M | $14.91M | $14.71M | $10.55M | $9.66M | $12.36M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $30.43M | $32.52M | $33.36M | $29.77M | $27.43M | $30.53M | $30.67M | $26.83M | $26.24M | $29.23M |
| Stockholders' Equity | $107.25M | $136.91M | $156.67M | $174.63M | $127.97M | $151.97M | $174.67M | $191.45M | $208.78M | $225.85M |
| Retained Earnings | ($514.10M) | ($480.42M) | ($454.86M) | ($428.73M) | ($401.71M) | ($374.23M) | ($348.39M) | ($327.35M) | ($307.01M) | ($287.31M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($29.89M) | - | - | - | ($23.36M) | - | - | - | ($24.45M) | - |
| Investing Cash Flow | $54.90M | - | - | - | $29.81M | - | - | - | $9.40M | - |
| Financing Cash Flow | $300.0K | - | - | - | $96.0K | - | - | - | $253.0K | - |
| CapEx | $102.0K | - | - | - | $187.0K | - | - | - | $88.0K | - |
| Free Cash Flow | ($30.00M) | - | - | - | ($23.54M) | - | - | - | ($24.54M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.89 | - | - | - | 0.86 | - | - | - | 1.25 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -24.5% | - | -13.8% | -13.2% | -17.7% | - | -10.2% | -9.3% | -8.4% | - |
| Return on equity | -31.4% | - | -16.7% | -15.5% | -21.5% | - | -12.0% | -10.6% | -9.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 7.09 | 8.15 | 9.04 | 12.39 | 11.06 | 10.77 | 12.47 | 18.54 | 21.97 | 18.76 |
| Quick ratio | 7.09 | 8.15 | 9.04 | 12.39 | 11.06 | 10.77 | 12.47 | 18.54 | 21.97 | 18.76 |
| Cash ratio | 5.08 | 3.24 | 2.53 | 7.23 | 3.14 | 2.13 | 1.73 | 2.85 | 2.72 | 3.32 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.28 | 1.24 | 1.21 | 1.17 | 1.21 | 1.20 | 1.18 | 1.14 | 1.13 | 1.13 |
| Liabilities / Assets | 0.22 | 0.19 | 0.18 | 0.15 | 0.18 | 0.17 | 0.15 | 0.12 | 0.11 | 0.11 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.2x | - | 2.6x | 2.1x | 2.3x | - | 2.5x | 2.0x | 1.9x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -20.1% | - | -20.1% | -25.7% | -30.1% | - | -13.4% | -12.3% | -14.8% | - |
| Net income growth (YoY) | -22.6% | - | -24.2% | -32.9% | -39.5% | - | -13.7% | -11.1% | -12.8% | - |
| EPS growth (YoY) | 9.1% | - | 4.8% | -14.6% | -37.5% | - | 12.5% | 14.6% | 13.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -27.4% | - | - | - | 4.1% | - | - | - | -48.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -16.2% | -9.9% | -10.3% | -8.8% | -38.7% | -32.7% | 15.1% | 15.0% | 15.8% | 15.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Aura Biosciences against the 5 most active filers in the same SIC group.